Funding for this research was provided by:
Seventh Framework Programme (FP7-HEALTH-2010-MEDIA)
Agence Nationale de la Recherche (ANR-15-RHU-0004, ANR-15-IDEX-04-LUE)
European Society of Cardiology (R-2018-18686)
Received: 9 March 2020
Accepted: 17 July 2020
First Online: 24 August 2020
Ethics approval and consent to participate
: The study protocol complied with the Declaration of Helsinki and was approved by the respective Ethics Committees of the participating institutions. Written informed consent was provided by all patients (ExternalRef removedidentifier: NCT02446327).
: Not applicable
: This study was supported by a grant from the European Union (FP7-HEALTH-2010-MEDIA), by the French Programme Hospitalier de Recherche Clinique (PHRC), and by the RHU Fight-HF, a public grant overseen by the French National Research Agency (ANR) as part of the second “Investissements d’Avenir” program (reference: ANR-15-RHU-0004), the GEENAGE (ANR-15-IDEX-04-LUE) program, by the Contrat de Plan Etat Région Lorraine and FEDER IT2MP. N-LA was supported by a Miguel Servet contract CP13/00221 from the “Instituto de Salud Carlos III-FEDER”. WJP and LvH were supported by CVON, Dutch Heart Foundation, The Hague, The Netherlands (RECONNECT and EARLY-HFpEF projects). AM received speaker’s honoraria from Orion, Otsuka, Philips, Roche, and Servier. AM received fees as a member of the advisory board and/or Steering Committee and/or research grant from Adrenomed, Epygon, Neurotronik, Roche, Sanofi, and Sphyngotec. AM owns shares in S-Form Pharma. SS acknowledges funding received from the European Society of Cardiology in the form of an ESC Research Grant (R-2018-18686).